KAKKIS EMIL D 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Aug 7, 2024
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO
Transactions
- Sale
Common Stock
2024-08-06$50.17/sh−20,000$1,003,400→ 2,243,985 total(indirect: See FN)
Holdings
- 564,597
Common Stock
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
- [F3]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F4]Includes 684 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on April 30, 2024.